Frequently Asked Questions
Why did you start this site?We welcome the goals of using a science based approach to decisions regarding COVID-19, but noticed that the sheer volume of research and data, and the frequently contradictory conclusions from equally qualified experts, made it extremely difficult for anyone to choose the best options. Moreover, decision makers were very suddenly thrown into positions where they needed to make very rapid and very public decisions. The fact that the science based approaches resulted in different decisions around the world highlights this difficulty.
Whether it be treatments or interventions, the plethora of seemingly similar quality research supporting contradictory positions, and the use of digital echo chambers, facilitates widespread confirmation bias - evidence supporting any initial position can be easily found. Self-serving bias and cognitive dissonance further make it challenging to alter positions, especially for those taking very public and strong positions with serious implications.
We felt that attempts to organize and make the research and data easier to navigate, highlighting areas of applicability, and analyzing limitations, could be beneficial. For example, we noticed that treatment delay was often being ignored. Results for an antiviral tested several days after symptoms, for example, cannot be generalized to results for early use.
What is the search strategy for papers?All significant original contributions related to the use of the treatments we cover, including searches of the typical sources augmented by contributions from the community. Covering all research is important because it is easy to choose a search strategy that results in a subset of papers reporting a desired conclusion. This is especially so if one takes the conclusions reported in papers at face value without examining the actual data, methods, or regions of applicability.
How do you choose the treatments?We catalog 1,974 potential treatments, of which we currently analyze 47 of the most effective, promising, and widely used early treatments. There are also many treatments that are helpful for late stage patients, however we currently focus on early treatment.
Who is @CovidAnalysis?We are PhD researchers, scientists, people who hope to make a contribution, even if it is only very minor. You can find our research in journals like Science and Nature. We have little interest in adding to our publication lists, being in the news, or being on TV (we have done all of these things before but feel there are more important things in life now).
What treatments do you recommend?We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and current situation.
Why should we trust @CovidAnalysis?There is no need to. We provide organization and analysis, but all sources are public and verifiable. For the meta-analyses, all data required to reproduce the analysis is contained in the appendix, with direct links to the original source papers.
Who funds this research?We have no funding, this is done in our spare time and we pay the web hosting fees personally (about $100 per month).
How can I donate?We don't accept donations (it could be a conflict of interest).
Can we use your graphs?Yes. You can use any of our work free of charge.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.